Provided by Tiger Fintech (Singapore) Pte. Ltd.

Applied DNA Sciences

5.37
-0.1400-2.54%
Post-market: 4.68-0.6900-12.85%18:08 EDT
Volume:153.07K
Turnover:832.56K
Market Cap:2.33M
PE:0.00
High:5.95
Open:5.40
Low:5.27
Close:5.51
Loading ...

Applied DNA Sciences Faces Nasdaq Delisting Hearing

TIPRANKS
·
3 hours ago

Applied DNA Sciences Faces Potential Nasdaq Delisting Due to Bid Price Rule Non-Compliance

Reuters
·
3 hours ago

Top Premarket Gainers

MT Newswires Live
·
Yesterday

Applied DNA Sciences trading halted, news pending

TIPRANKS
·
31 May

Applied DNA Sciences Announces 1-for-15 Reverse Stock Split Effective June 2, 2025

Reuters
·
29 May

Applied DNA Sciences Holds Annual Stockholder Meeting

TIPRANKS
·
23 May

Applied DNA Sciences Inc. Conducted Annual Stockholder Meeting

Reuters
·
23 May

Applied DNA Sciences Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Applied DNA Sciences Q2 EPS $(15.35) Up From $(265.45) YoY, Sales $983.37K Up From $929.63K YoY

Benzinga
·
16 May

Applied DNA Sciences: Q2 Total Revenues $983 Thousand

THOMSON REUTERS
·
16 May

Applied DNA Sciences Reports 44% Increase in Therapeutic DNA Segment Revenues and $3.3 Million Net Loss for Q2 Fiscal 2025

Reuters
·
16 May

Applied DNA Sciences Inc. to Release Q2 Fiscal 2025 Financial Results and Host Investor Update Call

Reuters
·
14 May

Applied DNA Sciences Inc expected to post a loss of $3.00 a share - Earnings Preview

Reuters
·
14 May

Applied DNA Sciences Inc expected to post a loss of $3.00 a share - Earnings Preview

Reuters
·
10 May

Applied DNA Sciences Inc expected to post a loss of $3.00 a share - Earnings Preview

Reuters
·
07 May

Applied DNA’s LineaRx ‘ready to support’ reshoring of drug development

TIPRANKS
·
21 Apr

Applied DNA Sciences Regains Nasdaq Compliance on Minimum Bid Price Rule

MT Newswires Live
·
08 Apr

Applied DNA regains compliance with Nasdaq minimum bid price rule

TIPRANKS
·
08 Apr

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

ACCESS Newswire
·
08 Apr

Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement

ACCESS Newswire
·
01 Apr